6 known cases. View patent page →
Celgene asserted multiple patents, including the '554 patent, against Natco's lenalidomide ANDA No. 201452. The '554 claims were dismissed without prejudice by stipulation on March 26, 2015; the overall case settled with a consent judgment entered January 4, 2016, and terminated January 5, 2016.
Celgene Corp. and Children's Medical Center Corp. sued Barr Laboratories over thalidomide ANDA; the '784 patent was among the patents-in-suit. The case was dismissed after Barr withdrew its ANDA, with Barr's antitrust counterclaims dismissed with prejudice and patent claims dismissed without prejudice.
Celgene sued Dr. Reddy's Laboratories over generic lenalidomide; the asserted patents included the '784 patent along with 6,315,720, 6,561,977, and 8,626,531. The case settled in 2020, with DRL licensed to sell volume-limited generic lenalidomide after March 2022 and unlimited from no earlier than January 31, 2026.
Celgene sued Hikma Pharmaceuticals International over generic lenalidomide; the asserted patents included the '784 patent and eight other patents. The case was terminated on 2019-09-18.
Celgene's Hatch-Waxman ANDA suit against Barr Laboratories, filed in D.N.J. The narrative lists it among verified litigation naming US 6,869,399, and notes that the Barr and Lannett suits asserted a bundle of Celgene thalidomide patents including '501, '720, '977, and '784. The outcome on the '399 patent is unconfirmed.
Celgene's Hatch-Waxman ANDA suit against Lannett Holdings, filed in D.N.J. The narrative lists it among verified litigation naming US 6,869,399, and notes that the Barr and Lannett suits asserted a bundle of Celgene thalidomide patents including '501, '720, '977, and '784. The outcome on the '399 patent is unconfirmed.